

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete If Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		Application Number	09/910,208		
		Filing Date	July 20, 2001		
		First Named Inventor	Jiro Hitomi		
		Art Unit	1644 (CONF. #4894)		
		Examiner Name	Haddad, Maher M.		
Sheet	1	of	1	Attorney Docket Number	MM4454

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
		FLORENCE GULGNARD, ET AL., Third European Symposium on Calcium Binding Proteins in Normal and Transformed Cells, Zurich, March 6-9, 1994, Programme Abstracts Miniposters		✓
		Metal-Based Drugs (1994), Vol. 1, Issue 1, pp. 79-80		✓
		EVELYN C. ILG, ET AL., Biochem. Biophys. Res. Commun. (1996/8), Vol. 225, No. 1, pp. 146-150, Amino Acid Sequence Determination of Human S100A12 (P6, Calgranulin C, CGRP, CAAF		✓
		New Biochemical Experiment Class, 1992/6/15, pp. 343-360 (Japanese)		✓
		YOICHI HACHITANDA, ET AL., Prognostic Value of N-myc Oncogene Amplification and S-100 Protein Positivity in Children with Neuroblastic Tumors, Acta Pathol Jpn (1992, Vol. 42,		✓
		DIETER ENGELKAMP, ET AL., Six S100 Genes Are Clustered on Human Chromosome 1Q21....; Proc. Natl. Acad. Sci. USA (1993), Vol. 90, pp. 6547-6551		✓
		ANNE-CHRISTINE DIANOUX, ET AL., The 23-Kilodalton Protein, A Substrate of Protein Kinase C, in Bovine Neutrophil Cytosol...; Biochemistry (1992), Vol. 31, No. 25, pp 5898-5905		✓
		MARIAN A.J. WETERMAN, ET AL., Expression of Calycyclin in Human Melanoma Cell Lines Correlates...; Cancer Res. (1992), Vol. 52, No. 5, pp 1291-1296		✓
		J-W. HUANG, ET AL., Heterogeneity and Multiple Expression of Intermediate Filament Proteins...; Anticancer Res. (1992), Vol. 12, No. 4, pp. 1107-1114		✓

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
The collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.